Start with obesity, then reuse UniProt P32245 as the stable protein anchor across project notes and exports.
CHEMBL259 Target Snapshot
Melanocortin receptor 4 · SINGLE PROTEIN · Homo sapiens
Research home keeps recent targets
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Switch target
Move to another high-traffic target or paste a specific ChEMBL target ID.
Frame the target before identity details
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-13Melanocortin receptor 4 shows approved-linked disease relevance led by obesity. 5 more disease programs remain visible in the same review block. 2 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt P32245. Start with obesity, then reuse UniProt P32245 as the stable protein anchor across project notes and exports.
Melanocortin receptor 4 shows approved-linked disease relevance led by obesity. 5 more disease programs remain visible in the same review block. 2 linked drugs remain visible in the same block.
Start review with obesity because it currently carries approved-linked support. Linked drugs include SETMELANOTIDE, SETMELANOTIDE ACETATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyMelanocortin receptor 4
Review this target as Melanocortin receptor 4, mapped to UniProt P32245. Sequence length is 332 aa.
Protein source · UniProt accession via ChEMBL component mappingCross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Melanocortin receptor 4 as ChEMBL target CHEMBL259, mapped to UniProt P32245. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Start with the right source
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Melanocortin receptor 4 is the right protein anchor across sources, using UniProt P32245 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why obesity is currently framed as approved-linked support. It currently carries 2 linked drugs in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardBasic Information
Verify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Melanocortin receptor 4 |
| Target Type | SINGLE PROTEIN |
| Organism | Homo sapiens |
| UniProt | P32245 |
Next Actions
UniProt Target Context
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Melanocortin receptor 4 |
| UniProt Accession | P32245 |
| Component Type | Protein |
| Sequence Length | 332 aa |
Melanocortin receptor 4
How to read this target
Review this target as Melanocortin receptor 4, mapped to UniProt P32245. Sequence length is 332 aa.
Disease Relevance & Evidence Level
Open Targets-ready disease context using the current target-indication evidence contract.
Melanocortin receptor 4 shows approved-linked disease relevance led by obesity. 5 more disease programs remain visible in the same review block.
How to read disease relevance
Start review with obesity because it currently carries approved-linked support. Linked drugs include SETMELANOTIDE, SETMELANOTIDE ACETATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Clinical Phase Distribution
Activity Type Distribution
Top Inhibitors (by pChEMBL)
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL4798971 | 10.82 | Ki | 0.015 | Preclinical |
| CHEMBL4794168 | 10.8 | Ki | 0.01585 | Preclinical |
| CHEMBL4794121 | 10.78 | Ki | 0.0166 | Preclinical |
| CHEMBL441738 | 10.77 | EC50 | 0.017 | Approved |
| CHEMBL413212 | 10.74 | EC50 | 0.018 | Preclinical |
| CHEMBL428615 | 10.72 | EC50 | 0.019 | Preclinical |
| CHEMBL4777048 | 10.71 | Ki | 0.0195 | Preclinical |
| CHEMBL4793821 | 10.68 | Ki | 0.02089 | Preclinical |
| CHEMBL4788071 | 10.68 | Ki | 0.021 | Preclinical |
| CHEMBL4794990 | 10.59 | Ki | 0.0257 | Preclinical |
pChEMBL Value Distribution
Approved Drugs
Assay Landscape
Binding — 336 assays, 3,011 compounds
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 175 | 2,139 | 7.2 |
| single protein format | 148 | 530 | 7.3 |
| assay format | 7 | 264 | 7.1 |
| cell membrane format | 6 | 78 | 7.8 |
Functional — 288 assays, 1,389 compounds
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 217 | 968 | 7.3 |
| assay format | 68 | 395 | 7.3 |
| single protein format | 2 | 0 | — |
| cell membrane format | 1 | 26 | 8.8 |
ADME — 6 assays, 12 compounds
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 6 | 12 | 7.5 |